Kirsty Cuthill

Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B‐Cell Non‐Hodgkin Lymphoma

Wouter Verhaar, Flores Weverling, Jahanzaib Khwaja, Despina Trajanova et autres

Immunoglobulin amyloid light-chain (AL) amyloidosis is a rare disorder in which misfolded monoclonal light chains deposit within organs, resulting in organ damage. Although the majority of AL amyloidosis is associated with an underlying plasma cell clone, approximately 5%–7% of cases are associated …

nl, gb, de, dk, us (code pays fourni par la source)

Scleredema of Buschke: 2 cases with a remarkable response to treatment of the underlying paraprotein

E. Vetsiou, L. Adams, Marianna Philippidou, Rabi Nambi et autres

gb (code pays fourni par la source)

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

Lise J Estcourt, Zoe McQuilten, Peter Bardy, Merrole Cole‐Sinclair et autres

Safety and Efficacy of Dara-VTD Induction and Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients Presenting with Renal Failure - a Tertiary Centre UK Experience on Behalf of the UK-MRA

Adrian Maraj, Katharine Bailey, Asma Batool, Reuben Benjamin et autres

Introduction - Renal failure (est glomerular filtration rate, eGFR <30ml/min) in newly diagnosed transplant eligible multiple myeloma (NDTEMM) remains high, affecting up to 20% of patients. Management is challenging, with limited data on optimal induction as these patients are often excluded from …

gb (code pays fourni par la source)

Consideration of Tandem Autologous Stem Cell Transplant for Patients with Multiple Myeloma- a Large UK Single Centre Retrospective Analysis

Anna Corby, Katharine Bailey, Arief Gunawan, Kirsty Cuthill et autres

Introduction For patients with newly diagnosed multiple myeloma (MM), an autologous stem cell transplant (autoHSCT) remains the standard of care for patients who are fit enough. Despite advances in induction treatment, patients with adverse genetics have a poorer prognosis. In patients with …

gb (code pays fourni par la source)

P-338 High Frequency of Electrolyte Derangement and Low Frequency of Transfusion Requirement Post Melphalan Autologous Bone Marrow Transplant – a Single Center Experience

Sneha Balakrishnan, Catriona Gahan, Michelle Kenyon, Dominic Thurgood et autres

P-393 A real-world UK experience of Daratumumab, Velcade, Dexamethasone and Carfilzomib, Lenalidomide, Dexamethasone as second line therapies in the UK: a South East London retrospective

Dogan Yildiz, Sanela Kahrimanovic, Youssef Salam, Kirsty Cuthill et autres

P-337 Lower Utilisation of Autologous Stem Cell Transplant in Patients With Multiple Myeloma From Black Caribbean and Black African Ethnic Groups in the UK – a Single Center Experience

Arief Gunawan, Damaris Adebambo, Ben Jones, Katharine Bailey et autres

P-087 Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience

Pablo Tenorio Feixas, Catrin Cox, Xavier Peer, Kirsty Cuthill et autres

A case of ulcerated nodules in association with a monoclonal gammopathy

Sheena Bhadresha, Kirsty Cuthill, J R Salisbury, Carolina Fernandez et autres

A 75-year-old man with a monoclonal gammopathy of undetermined significance presented with a 10-year history of painful ulcerated nodules on the dorsum of the right foot (Fig 1, A). Skin biopsy of a similar plaque on the left arm showed necrobiosis with …

gb, us (code pays fourni par la source)

Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience

Christianne Bourlon, Katharine Bailey, Reuben Benjamin, Kirsty Cuthill et autres

Introduction In newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplantation (ASCT), daratumumab plus, bortezomib, thalidomide, and dexamethasone (D-VTd) followed by high-dose melphalan with ASCT, is considered standard of care in Europe. The CASSIOPEIA trial reported a lower stem …

gb (code pays fourni par la source)

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Reuben Benjamin, Nitin Jain, Marcela V. Maus, Nicolas Boissel et autres

gb, us, fr, jp (code pays fourni par la source)